Combination of Haloperidol and Magnesium for Delirium Prevention in Critically Ill Elderly
Status:
Completed
Trial end date:
2023-11-04
Target enrollment:
Participant gender:
Summary
Objective: The aim of this randomized double blinded study is to investigate the
effectiveness and safety of the prophylactic use of haloperidol with or without magnesium
(Mg) for delirium in high risk elderly patients postoperatively.
Patients and methods: 135 patients aged ≥ 65< 80 years old with PRE-DELIRIC Score 50% or more
(20) were admitted to the ICU non-intubated following major non cardiac surgeries randomized
into 3 groups, Group I received 1 mg haloperidol intravenously 3 times daily and magnesium
sulfate 4 g intravenous infusion (IVI) in 1st day (diluted in 50 ml D5W over 24 hours) then
2g IVI over 24 hours (diluted in 50 ml D5W over 24 hours) for 3 days, Group II received 1 mg
haloperidol intravenously 3 times ,Group III received 1 mL 0.9% of sodium chloride
intravenously 3 times daily. The primary outcome of the study will be the incidence of
delirium.